WO2009149306A9 - Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds - Google Patents

Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds Download PDF

Info

Publication number
WO2009149306A9
WO2009149306A9 PCT/US2009/046330 US2009046330W WO2009149306A9 WO 2009149306 A9 WO2009149306 A9 WO 2009149306A9 US 2009046330 W US2009046330 W US 2009046330W WO 2009149306 A9 WO2009149306 A9 WO 2009149306A9
Authority
WO
WIPO (PCT)
Prior art keywords
depleting compounds
complement
methods
monoclonal antibody
complement depleting
Prior art date
Application number
PCT/US2009/046330
Other languages
French (fr)
Other versions
WO2009149306A2 (en
Inventor
William D. St. John
George Weiner
Carl-Wilhelm Vogel
Paul W. Finnegan
Kevin L. Stark
David C. Fritzinger
Original Assignee
Incode Biopharmaceutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incode Biopharmaceutics, Inc. filed Critical Incode Biopharmaceutics, Inc.
Publication of WO2009149306A2 publication Critical patent/WO2009149306A2/en
Publication of WO2009149306A9 publication Critical patent/WO2009149306A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2009/046330 2008-06-04 2009-06-04 Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds WO2009149306A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US5877708P 2008-06-04 2008-06-04
US61/058,777 2008-06-04
US10453108P 2008-10-10 2008-10-10
US61/104,531 2008-10-10
US11493908P 2008-11-14 2008-11-14
US61/114,939 2008-11-14

Publications (2)

Publication Number Publication Date
WO2009149306A2 WO2009149306A2 (en) 2009-12-10
WO2009149306A9 true WO2009149306A9 (en) 2010-03-04

Family

ID=41398875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/046330 WO2009149306A2 (en) 2008-06-04 2009-06-04 Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds

Country Status (1)

Country Link
WO (1) WO2009149306A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012010116A (en) 2010-03-01 2013-02-26 Alexion Pharma Inc Methods and compositions for treating degos' disease.
PL2560658T3 (en) * 2010-04-21 2017-08-31 Ventirx Pharmaceuticals, Inc. Enhancing antibody-dependent cellular cytotoxicity
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2016356715B2 (en) * 2015-11-20 2023-12-14 Memorial Sloan-Kettering Cancer Center Modulating permeability of the blood cerebrospinal fluid barrier

Also Published As

Publication number Publication date
WO2009149306A2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
HK1253579A1 (en) Monoclonal anti-gt468 antibodies for treatment of cancer
EP2152754B8 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
HK1209653A1 (en) Monoclonal antibodies for tumor treatment
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
HRP20180485T1 (en) Monoclonal antibodies for treatment of cancer
HK1119721A1 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
HRP20150007T8 (en) Treatment of tumors using specific anti-l1 antibody
WO2009149306A9 (en) Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds
WO2008118324A3 (en) Composition and method of treating cancer with an anti-uroplakin ib antibody
IL211752A0 (en) Antibody combinations and use of same for treating cancer
IL207478A0 (en) Monoclonal antibodies for tumor treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09759465

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09759465

Country of ref document: EP

Kind code of ref document: A2